UBS raised the firm’s price target on BridgeBio (BBIO) to $82 from $72 and keeps a Buy rating on the shares. The company will report Phase 3 data for autosomal dominant hypocalcemia type this fall, which is an “underappreciated opportunity” for BridgeBio, the analyst tells investors in a research note. UBS has conviction in the Phase 3 success and upped its peak sales estimate to $1B from $700M. The firm reiterates BridgeBio as a top pick and see ADH1 as a “valuable and underappreciated” pipeline asset for the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Optimistic Buy Rating for BridgeBio Pharma: Promising ADH1 Treatment and Market Potential
- BridgeBio Pharma: Poised for Growth with Promising Pipeline and Upcoming Catalysts
- BridgeBio Pharma’s Encaleret: Promising Developments and Potential Market Impact
- BridgeBio announces results from Phase 2 study of encaleret
- 3 Best Stocks to Buy Now, 9/3/2025, According to Top Analysts